Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
BRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $2.55
Previous CloseN/A
Volume34.37K
Average Volume (3M)739.82K
Market Cap
$10.52M
Enterprise Value$1.10M
Total Cash (Recent Filing)$884.38K
Total Debt (Recent Filing)$162.32K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 20, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding6,919,919
10 Day Avg. Volume2,059,258
30 Day Avg. Volume739,821
Standard Deviation21.99
R-Squared0.02
Alpha2.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.74
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.54
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$8.00Price Target Upside426.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
BioRestorative Therapies News
PremiumCompany Announcements
BioRestorative Therapies Issues Regulation FD Disclosure
PremiumCompany Announcements
BioRestorative Therapies Q3 2024 Financial Update---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive signals are observed in the ongoing P2 study of BRTX-100, particularly as all four patients reached the response threshold in the interim data.
Regulatory MilestonesBioRestorative has gained Fast Track designation for the lumbar spinal pain program, potentially enabling priority review and reflecting the positive safety and efficacy data reported to date.
Bears Say
Market CompetitionIncreasing regulatory acceptance of MSCs is noted, with other companies making advancements in this space.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.26% Insiders
1.07% Mutual Funds
1.72% Other Institutional Investors
78.65% Public Companies and Individual Investors
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $1.03 and its highest was $2.55 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is $10.52M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is May 20, 2025 which is in 78 days.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on Nov 12, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.303.
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Undervalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate is -0.26.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 6,919,919 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -6.098%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
---
Company Description
BioRestorative Therapies
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The company is developing the following scientific initiatives: brtxDISC Program offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. The ThermoStem Program focuses on treatments for metabolic disorders and obesity and uses brown fat stem cells, which initial research indicates increased caloric burning and reduced glucose and lipid levels in the body. It also offers plant stem cell-based facial creams and products under the Stem Pearls brand. Biorestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
---
BRTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was optimistic, with strong preliminary results for BRTX-100 showing promise beyond FDA benchmarks, a solid financial position, and potential for accelerated approval. However, the positive outlook is tempered by the limited data available and uncertainty around the release of unblinded results.Read More>---
BRTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(426.32% Upside)
Technical Analysis
Best Analysts Covering BRTX
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-28.92%
reiterated a buy rating 4 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -28.92% per trade.
---